Historical record - last NADAC effective date: 7/18/2018
Product Information
DEMECLOCYCLINE 150 MG TABLET is a generic product labeled by PuraCap Laboratories LLC, priced at $3.0156 per EA under NDC 24658071001. Its NADAC has been published 9 times since Jul 18, 2018.
FDA first approved this application on Aug 18, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
PuraCap Laboratories LLCNDC
24658071001
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
7/18/2018
Active Ingredients
DEMECLOCYCLINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA065447FDA Approved
8/18/2015
TE Code
AB
On Market Since
10/7/2017
Pharmacological Classes
Price Statistics
The NADAC for DEMECLOCYCLINE 150 MG TABLET has been published 9 times since Jul 18, 2018, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.0156 per EA |
|---|---|
| All-time high | $3.0156 (Sep 12, 2018) |
| All-time low | $3.0156 (Jul 18, 2018) |
| Median price | $3.0156 |
| Average price | $3.0156 |
| Largest weekly change | 0.0% (Jul 25, 2018) |
| Weeks tracked | 9 |
| Tracking since | Jul 18, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Sep 12, 2018 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 25% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
PuraCap Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Demeclocycline Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tetracycline-class Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEMECLOCYCLINE 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DEMECLOCYCLINE 150 MG TABLET, manufactured by PuraCap Laboratories LLC, is $3.0156 per EA (NDC 24658071001), effective Sep 12, 2018.
How has the price of DEMECLOCYCLINE 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for DEMECLOCYCLINE 150 MG TABLET has held within roughly two percent of its current level. It has been tracked across 9 weekly CMS publications since Jul 18, 2018.
What are the highest and lowest recorded NADAC prices for DEMECLOCYCLINE 150 MG TABLET?
Since Jul 18, 2018, the NADAC for DEMECLOCYCLINE 150 MG TABLET has ranged from a low of $3.0156 (Jul 18, 2018) to a high of $3.0156 (Sep 12, 2018), with a median of $3.0156 per EA.
Are there cheaper alternatives to DEMECLOCYCLINE 150 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DEMECLOCYCLINE 150 MG TABLET, is $2.2726 per EA — about 25% below DEMECLOCYCLINE 150 MG TABLET.
Who manufactures DEMECLOCYCLINE 150 MG TABLET?
DEMECLOCYCLINE 150 MG TABLET (NDC 24658071001) is labeled by PuraCap Laboratories LLC, and CMS classifies it as a generic product.